Canada's Vitalhub Q1 revenue rises 47%, beats estimates

Vitalhub

07/05/2026 23:04

Overview

Canada health software firm's Q1 revenue rose 47% yr/yr, beating analyst expectations

Adjusted EBITDA for Q1 rose 42% yr/yr to C$8.0 mln

Growth driven by acquisitions and organic expansion, with ARR up 34% yr/yr

Outlook

Company did not provide specific financial guidance for the current or future periods

Result Drivers

ACQUISITIONS - Company said acquisitions contributed 22% to annual recurring revenue growth and supported overall revenue gains

ORGANIC GROWTH - Company reported 11% annual organic ARR growth and noted strong billings and renewals

OPERATIONAL EFFICIENCY - CEO said integration work from acquisitions is progressing well and driving operational efficiency

Company press release: ID:nGNX2pfDl1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
C$31.90 mln
C$31.42 mln (10 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Vitalhub Corp is C$12.50, about 59.2% above its May 6 closing price of C$7.85

The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 34 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)